Reuters Health News Summary
Following is a summary of current health news briefs.
Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion
Drugmaker Eli Lilly has signed an oncology research collaboration and licensing agreement worth up to $5.9 billion with Stipple Bio, the privately held biotech firm said on Monday. The deal gives Lilly access to Stipple Bio's technology, which is designed to identify molecules that can distinguish cancer cells from healthy tissue, potentially enabling Lilly to develop therapies that are more effective and cause fewer side effects.
J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says
Johnson & Johnson could announce a deal as soon as Monday to buy Texas-based biotech Ollin Biosciences for up to $3.4 billion, the Financial Times said, citing people familiar with the matter. Here are some details:
CG Oncology's immunotherapy reduces risk of tumor recurrence in bladder cancer trial
CG Oncology said on Monday its experimental immunotherapy reduced the risk of tumor recurrence by 68% in certain patients with a type of bladder cancer, meeting the main goal of a late-stage study. Its shares jumped more than 30% to $98 in premarket trading.
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
AstraZeneca said on Monday it has won two US drug approvals, an expanded bladder cancer use for its immunotherapy Imfinzi and a first-of-its-kind therapy for a rare muscle-weakening disorder. The US Food and Drug Administration approved Imfinzi, combined with enfortumab vedotin, a targeted therapy prior to surgery, for muscle-invasive bladder cancer patients who are ineligible for or have refused cisplatin-based chemotherapy
Sellas' cancer vaccine extends survival in blood cancer trial
Sellas Life Sciences said on Tuesday its experimental vaccine helped patients with a type of blood cancer live longer in a late-stage trial. The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukemia, a fast-growing cancer of the blood and bone marrow.
J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion
Johnson & Johnson said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion, expanding its pipeline of eye disease therapies. Ollin's experimental eye disease treatment, OLN324, will help J&J strengthen its presence in an area where it has a limited footprint, despite its large contact lens business.
Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet
Eli Lilly has agreed to acquire privately held biotech Calytrix Bio for up to $1.5 billion in cash, as it looks to expand the development of treatments for rare blood cancers. The move, announced on Monday by Calytrix, is the latest in a string of acquisitions by the Indianapolis-based pharmaceutical giant as it works to diversify beyond its blockbuster diabetes and weight-loss franchise.
Teva settles US states' drug price-fixing case
Teva Pharmaceutical Industries has settled long-running litigation by most US states accusing the drugmaker and dozens of other defendants of conspiring to fix prices on dozens of generic drugs. Chief Judge Michael Shea of the federal court in Hartford, Connecticut, put the case on hold on Monday after both sides reached an agreement in principle to settle, court records show. Settlement terms were not disclosed. The case was brought by 45 US states, Washington, DC and two US territories.
Rhythm drug shows sustained weight reduction in patients with brain damage-related obesity
Rhythm Pharmaceuticals said on Monday its therapy for a rare form of obesity caused by brain damage showed clinically meaningful body weight reduction in patients after two years of therapy. Shares of the company fell 1.4% in after-hours trading.
Barrick furloughing some Congo mine personnel over Ebola concerns
Canadian miner Barrick said it was furloughing non-essential personnel and reinforcing health screenings after two Ebola cases were confirmed near its Kibali gold mine in northeastern Democratic Republic of Congo. Reuters reported last week that Barrick in an internal memo said it was furloughing some employees and subcontractors at the Kibali mine after health authorities confirmed the two cases, which were fatal
L'Oreal US settles hair relaxer cancer cases during first trial
Four women who said they were diagnosed with cancer as a result of chemical hair straightening products reached a settlement on Monday with L’Oreal's US subsidiary and other companies during a trial in Chicago, according to their attorneys. The women are among thousands who have sued the companies, alleging that years of using chemical hair straighteners caused them to develop gynecologic cancers. The cases, which were the first to go to trial, settled for a confidential sum, the lawyers said.
Africa CDC says Ebola outbreak still out of control six months since it was declared
Africa's top public health agency said on Sunday that the Ebola outbreak in Congo was still out of control six months after it was declared, citing problems including deadly attacks on health workers, unpaid staff and a lack of resources. "We are all in agreement today to say that this outbreak is still serious, and is still not under control," Jean Kaseya, director-general of the Africa CDC, told Reuters in an interview.
Exclusive-Authorities raid factory making illegal Chinese vapes in the US
US authorities uncovered a factory producing illegal vapes last month, according to police and photographs seen by Reuters, in a sign Chinese manufacturers have moved some production to the United States following a crackdown on imported devices. Chinese-owned disposable vape brands have come to dominate the US market — the world's largest for smoking alternatives — even though they lack the authorisation from the US Food and Drug Administration required for their legal sale.
Pennsylvania measles cases rise to 1,561, state health department says
The number of measles cases in Pennsylvania reached 1,561 as of Monday, up 19 from the previous update on Friday, as the state battles its worst outbreak of the disease in decades. Here are more details:
DNA drug developer Seawolf launches with $100 million funding, Sanofi deal
Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi worth up to $1.2 billion, as it seeks to develop DNA-based medicines. The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics and others
Helus psychedelic depression drug succeeds in trial amid safety scrutiny
Helus Pharma said on Monday its experimental psychedelic drug significantly improved depression symptoms in a late-stage trial, but its US-listed shares fell more than 15% as investors focused on safety concerns, including a suicide attempt reported in the study. The drug, known as HLP003, is a modified version of psilocin, the compound responsible for the psychedelic effects of so-called "magic mushrooms." It is designed as an add-on therapy for patients who do not achieve relief from standard antidepressants alone.
Incyte says EU approves oral treatment for chronic skin disease
Incyte said on Monday the European Commission had approved its once-daily oral therapy for a type of chronic skin disease.
The drug, Povofortay, chemically known as povorcitinib, was approved for adults with moderate-to-severe hidradenitis suppurativa who have responded inadequately to, or cannot take, anti-tumor necrosis factor therapies.
Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain
Flagship Pioneering is opening its first lab for creating companies outside the United States, putting £100 million ($131.94 million) behind a new UK-based effort to fund and build AI-driven biotech companies, the venture firm said on Monday. The move is a first for a firm that has created more than 130 companies, including Moderna, and operated only from the United States for more than 25 years.
WHO says antimicrobial resistance efforts improve globally but remain off track for 2030 goals
More countries have adopted plans to combat antimicrobial resistance (AMR) this year, but most are failing to translate commitments into funded programs, leaving the world off pace to meet key 2030 targets, the World Health Organization said. Of 183 countries surveyed, 173 reported having a national action plan to tackle AMR, up from 79 in 2017. Only 42, however, said their plans were financed and implemented.
Gilead signs generic licensing deals for experimental Ebola drug
Gilead Sciences said on Monday it had signed royalty-free deals with three generic drugmakers to make its experimental Ebola prevention drug available in 127 mainly low- and lower-middle-income countries if it succeeds in trials and wins regulatory approvals. Here are more details:
US must intensify vaccination effort to regain measles-free status lost after 26 years
Public health experts say the US must drive vaccinations and disease surveillance in order to regain the hard-won measles-free status it held for 26 years that a Trump administration official said on Monday had been revoked. The Pan American Health Organization told the Trump administration in a letter on Friday that the United States had lost the status, the official said. PAHO is expected to make the formal announcement on Tuesday.
Explainer-Congo's Ebola outbreak is spreading and killing at a record pace
The Ebola outbreak in eastern Democratic Republic of Congo remains out of control six months after it was first declared, with case numbers and deaths still rising at a record pace. Despite an outpouring of aid, resource shortages, insecurity and poor coordination hamper efforts to contain the outbreak. Health workers have come under attack in communities that distrust outsiders.
US FDA declines to approve Summit lung cancer drug after trial misses key survival goal
The US Food and Drug Administration on Sunday declined to approve Summit Therapeutics' lung cancer drug ivonescimab, a setback for efforts to expand treatment for patients whose cancer has progressed after earlier therapies. In its so-called complete response letter, the FDA cited a late-stage trial showing that, while ivonescimab significantly delayed disease progression, it did not demonstrate a statistically significant improvement in overall survival.
US FDA approves Roche's oral treatment for advanced breast cancer
The US Food and Drug Administration approved Roche's oral treatment for certain patients with a type of advanced breast cancer, the regulator said on Monday. The drug, giredestrant, was approved in combination with everolimus for adults with estrogen receptor-positive, HER2-negative locally advanced or metastatic cancer, whose cancer carries an ESR1 mutation and has returned or worsened during or after hormone-based treatment.
Australia's Mayne Pharma jumps to 1-year high on $408 million Gedeon Richter takeover
Mayne Pharma said on Tuesday that Hungarian drugmaker Gedeon Richter had agreed to buy the Australian firm for an equity value of about A$604 million ($407.76 million), sending its shares soaring 86% to a one-year high. The deal put the stock on track for its best session on record, if the current gains hold, with shares last trading at A$5.97.
Summit shares drop after US FDA declines to approve lung cancer drug
Shares of Summit Therapeutics fell 14% on Monday after the US Food and Drug Administration declined to approve its experimental lung cancer drug ivonescimab. The regulator on Sunday cited the drug's failure to achieve statistically significant overall survival benefit in a late-stage study that was part of Summit's application.
US FDA approves at-home use of BioXcel's agitation drug
The US Food and Drug Administration on Monday approved at-home use of BioXcel Therapeutics' drug, Igalmi, for agitation associated with schizophrenia or bipolar disorder. The company last month completed the sale of nearly all its assets, including Igalmi, to a unit of Israel-based Teva Pharmaceuticals.
Google News